Articles published by Merck & Co., Inc.
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
October 01, 2024
From Merck & Co., Inc.
Via Business Wire
Tickers
MRK
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
September 11, 2024
From Merck & Co., Inc.
Via Business Wire
Tickers
MRK
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
September 04, 2024
From Merck & Co., Inc.
Via Business Wire
Tickers
MRK
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
September 04, 2024
From Merck & Co., Inc.
Via Business Wire
Tickers
MRK
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
August 09, 2024
From Merck & Co., Inc.
Via Business Wire
Tickers
MRK
Merck Announces Second-Quarter 2024 Financial Results
July 30, 2024
From Merck & Co., Inc.
Via Business Wire
Tickers
MRK
Merck Announces Fourth-Quarter 2024 Dividend
July 23, 2024
From Merck & Co., Inc.
Via Business Wire
Tickers
MRK
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.